transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Författare och institution:
Helen Tedeholm (-); Jan Lycke (-); Bengt Skoog (-); Vera Lisovskaja (Institutionen för matematiska vetenskaper, matematisk statistik, Chalmers/GU); J Hillert (-); C Dahle (-); J Fagius (-); S Fredrikson (-); A-M Landtblom (-); Clas Malmeström (-); C Martin (-); F Piehl (-); Björn Runmarker (-); L Stawiarz (-); M Vrethem (-); Olle Nerman (Institutionen för matematiska vetenskaper, matematisk statistik, Chalmers/GU); Oluf Andersen (-)
Publicerad i:
Multiple Sclerosis Journal, 19 ( 6 ) s. 765-774
Artikel, refereegranskad vetenskaplig
Fulltextlänk (lokalt arkiv):
Sammanfattning (abstract):
Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP).

Objective: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort.

Methods: We included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995–2004, n = 730) and a historical population-based incidence cohort (onset 1950–64, n = 186). We retrospectively analyzed the difference in time to SP, termed the “period effect” within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis.

Results: We found that the “period” affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53).

Conclusion: Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin
multipel skleros, DMD, progression, RRMS, SPMS, bromsmedicin
Postens nummer:
Posten skapad:
2014-10-16 18:16
Posten ändrad:
2016-08-22 10:30

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007